ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1920 • 2015 ACR/ARHP Annual Meeting

    Differential Production of Th17-Related Cytokines By Toll like Receptor (TLR)-Ligands-Stimulated Monocyte-Derived Dendritic Cells (Mo-DCs) from Systemic Sclerosis (SSc) Patients; Relevance of IL-22 and IL-33 According to Disease Subtype and Stage

    Tatiana Sofia Rodriguez-Reyna1, Adrián Caballero1, Luís Jiménez-Álvarez2, Gustavo Ramirez2, José Eduardo Márquez García2, Alfredo Cruz Lagunas3, Guadualupe Lima4, Janette Furuzawa-Carballeda5, Luis Llorente1 and Joaquin Zuniga6, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 3Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 6Immunology, Instituo Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico, Mexico

    Background/Purpose: Systemic sclerosis (SSc) patients exhibit alterations in innate and acquired cellular responses including an enhanced inflammatory response to toll like receptor (TLR) agonists that…
  • Abstract Number: 1921 • 2015 ACR/ARHP Annual Meeting

    Role of TLRs in the Abnormal Secretion of CXCL-4 By Plasmacytoid Dendritic Cells of Patients with Systemic Sclerosis

    Marie-Dominique Ah Kioon1, Eliza Pelrine2, Robert F. Spiera3, Jessica K. Gordon3 and Franck J. Barrat1, 1Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disorder of the connective tissue due to excessive extracellular matrix deposition, leading to fibrosis of the skin and…
  • Abstract Number: 1922 • 2015 ACR/ARHP Annual Meeting

    Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis

    Nicolas Dumoitier1,2,3,4, Sebastien Lofek2,3,5, Alexis Regent6, Jonathan London7, Benjamin Chaigne1,2,3,8, Benjamin Terrier2,7,9,10, Nadine Varin-Blank4,11 and Luc Mouthon1,2,4,6, 1Infection, Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, 2CNRS, UMR8104, Paris, France, 3Université Paris Descartes, Paris, France, 4Labex Inflamex, Université Sorbonne Paris Cité, Paris, France, 5Infection,Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, 6Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 7Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 8Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochinl, Paris, France, 9Infection, Immunité, Inflammation, Institut Cochin INSERM U1016, Paris, France, 10Université Paris Descartes, paris, France, 11UFR SMBH, INSERM, UMR978, Bobigny, France

    Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by fibroblasts activation, increased extra-cellular matrix synthesis associated with autoimmunity. However, the potential role…
  • Abstract Number: 1923 • 2015 ACR/ARHP Annual Meeting

    The Role of Inflammatory Myeloid Cell Compartment in Myocardial Fibrogenesis and Remodelling in Systemic Sclerosis

    Veronika Haunerdinger1, Przemyslaw Blyszczuk2, Elena Pachera1, Rucsandra Dobrota3, Britta Maurer1, Ulrich Grabmaier4, Karl Sotlar5, Oliver Distler1 and Gabriela Kania1, 1Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, 2Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland, 3Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Medical Clinic und Polyclinic I, Campus Großhadern, Maximilians University Munich, 81377 Munich, Germany, 5Institute of Pathology, Ludwig Maximilians University Munich, 81377 Munich, Germany

    Background/Purpose: During the last years, there was a shift in systemic sclerosis (SSc)-related causes of death, indicating cardiac involvement and inflammatory dilated cardiomyopathy (iDCM) as…
  • Abstract Number: 1924 • 2015 ACR/ARHP Annual Meeting

    Increased Stat1 and Stat 1 Phosphorylation in Patients with Systemic Sclerosis (SSc) 

    Martyna Skwarek, Julia Fantana, Babett Heschel, Martin Aringer and Christoph Kittel, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany

    Background/Purpose: To analyze Stat1 and phosphorylated Stat1, the interleukin-6 (IL-6) receptor-Stat3 axis, and membrane bound tumor necrosis factor (mTNF) and TNF receptors 1 and 2…
  • Abstract Number: 1925 • 2015 ACR/ARHP Annual Meeting

    Interleukin-35 Is Upregulated in Systemic Sclerosis and Its Serum Levels Are Increased in Early Disease

    Michal Tomcík1, Pawel Zerr2, Katrin Palumbo-Zerr2, Hana Storkanova1, Hana Hulejova3, Maja Spiritovic4, Ondrej Kodet5, Jiri Stork5, Radim Becvar1, Jiri Vencovsky1, Karel Pavelka6, Maria Filkova7, Jorg HW Distler2 and Ladislav Senolt8, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, 4Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, 5Department of Dermatology and Venereology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 6Charles University, Prague, Czech Republic, 7Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin-35 (IL-35) is the most recent addition to the IL-12 family, which also comprises IL-12, IL-23 and IL-27. IL-35 consists of two chains, p35/IL-12a…
  • Abstract Number: 1926 • 2015 ACR/ARHP Annual Meeting

    Wnt5a Activates Wnt/PCP-Signaling to Promote Fibroblast Activation and Fibrosis

    Chih-Wei Chen1, Neng-Yu Lin1, Yun Zhang1, Jingang Huang1, Katrin Palumbo-Zerr1, Alexandra Schambony2, Christian Beyer1, Georg Schett1 and Jeorg HW Distler1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Biology, Development Biology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: While canonical Wnt/beta-catenin signaling has been identified as a core pathway of fibrosis in SSc, non-canonical Wnt signaling pathways have not yet been analyzed.…
  • Abstract Number: 1927 • 2015 ACR/ARHP Annual Meeting

    Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc

    Peter J. Wermuth1 and Sergio A. Jimenez2, 1Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, 2Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Activated myofibroblasts are the primary mediators of the excessive synthesis and deposition of collagens and other extracellular matrix (ECM) macromolecules during the pathogenesis of…
  • Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting

    Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis

    Shadia Nada1, Farouk Abu Alhana2, Yongqing Wang2, Nezam Altorok3 and Bashar Kahaleh4, 1Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, 2The University of Toledo, Toledo, OH, 3Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, 4Medicine/Rheumatology, The University of Toledo, Toledo, OH

    Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…
  • Abstract Number: 1929 • 2015 ACR/ARHP Annual Meeting

    Somatic Mutations in Clonally Expanded Cytotoxic Lymphocytes in Patients with Newly Diagnosed Rheumatoid Arthritis

    Paula Savola1, Tiina Kelkka1, Hanna Rajala1, Antti Kuuliala2, Krista Kuuliala2, Samuli Eldfors3, Pekka Ellonen3, Sonja Lagstrom3, Rajiv Kumar Khajuria1, Taina Jaatinen4, Riitta Koivuniemi5, Heikki Repo2, Janna Saarela3, Kimmo Porkka1, Marjatta Leirisalo-Repo6 and Satu Mustjoki1, 1Department of Hematology, Hematology Research Unit Helsinki, University of Helsinki, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, 2Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland, 3Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 4Clinical Laboratory, Finnish Red Cross Blood Service, Helsinki, Finland, 5Department of Medicine, Division of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 6Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    Background/Purpose: In rheumatoid arthritis (RA), the mechanisms initiating immune dysregulation leading to joint damage are incompletely understood. Previous studies show that large CD8+ T cell…
  • Abstract Number: 1930 • 2015 ACR/ARHP Annual Meeting

    Identification of a Broadly Immunogenic Prevotella Copri T Cell Epitope in Patients with Rheumatoid Arthritis

    Annalisa Pianta1, Elise E. Drouin1, Sheila Arvikar2, Klemen Strle1, Jameson T. Crowley1, Qi Wang3, Catherine E. Costello3 and Allen C. Steere4, 1Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, 4Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Specific microorganisms in the gut microbiome may have a pathogenic role in rheumatoid arthritis (RA). Recently, Scher et al. showed that Prevotella copri, an…
  • Abstract Number: 1931 • 2015 ACR/ARHP Annual Meeting

    PLCe1 Mediates Cellular Adhesion Downstream of SDF-1 in T Cells

    Adam Mor1 and Marianne Strazza2, 1Rheumatology and Pathology, NYU Langone Medical Center, New York, NY, 2NYU, New York, NY

    Background/Purpose: The presentation of chemokines by endothelial cells results in chemoattraction of leukocytes that express the correlative chemokine receptors. In this way, chemokines direct leukocyte…
  • Abstract Number: 1932 • 2015 ACR/ARHP Annual Meeting

    IL-17A-Low CCR6+ Th Cell Populations of Patients with Rheumatoid Arthritis Are Pathogenic, Multidrug Resistant and Associated with DMARD and Glucocorticoid Treatment Response

    Jan Piet van Hamburg1, Sandra M.J. Paulissen2, Nadine Davelaar1, Mieke Hazes3 and Erik Lubberts1, 1Rheumatology and Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, 2Room Nb-84, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, 3Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

    Background/Purpose: CCR6+ T-helper (Th) cells and their pro-inflammatory cytokines including IL-17A are implicated in the pathogenesis of rheumatoid arthritis (RA). However, within the CCR6+ Th…
  • Abstract Number: 1933 • 2015 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patient T Cells Recognize Neutrophil Extracellular Traps

    Dana E. Orange1,2,3, Nathalie Blachere1, Salina Parveen1, John Fak1, Mayu Frank1 and Robert Darnell3,4,5, 1The Rockefeller University, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3The New York Genome Center, New York, NY, 4Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, NY, 5Howard Hughes Medical Institute, New York, NY

    Background/Purpose: The majority of patients with rheumatoid arthritis (RA) harbor anti-citrullinated peptide antibodies, which are correlated with more severe disease. Tetramer based assays have demonstrated…
  • Abstract Number: 1934 • 2015 ACR/ARHP Annual Meeting

    Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus

    Maud Wilhelm1, Fengjuan Wang2, Nicolas Schall2, Michael Faludi3, Jean Francois Kleinmann4, Emil P. Nashi5, Thierry Martin6, Jean Sibilia7, Jean-Louis Pasquali8, Daniel Wallace9 and Sylviane Muller10, 1Immunopathologie & Chimie Thérapeutique, CNRS, Strasbourg, France, 2CNRS, Strasbourg, France, 3761 Graham, McGill University, Mont-Royal, QC, Canada, 4Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 6Cnrs UPR9021, IBMC, Strasbourg, France, 7Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 8Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, 9Cedars-Sinai/UCLA, Los Angeles, CA, 10CNRS Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France

    Background/Purpose: P140 is a 21-mer peptide (sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K. In a multicenter, randomized, placebo-controlled…
  • « Previous Page
  • 1
  • …
  • 1815
  • 1816
  • 1817
  • 1818
  • 1819
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology